You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers from Ambry Genetics analyzed a set of DTC results sent to them for confirmation testing and found that 40 percent were false positives.
The partnership will integrate Ambry Genetics' and Invicro's technologies to expedite new drug discovery and development.
Konica Minolta paid $800 million up front for Ambry, with Ambry shareholders eligible to receive up to $200 million in future payments.
The deal will join the AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.
Ambry will provide genetic testing in NorthShore’s Genomic Health Initiative in hopes of moving precision medicine into clinical practice.
The company expects the deal will help it launch an immunostaining technology, expand into US pharma services, and establish itself as a genetic testing leader in Japan.
Konica said that the deal represents its first step toward building a presence in the precision medicine field, with an eye toward Japan and then Europe.
Through prospective pancreatic ductal adenocarcinoma testing, researchers saw germline mutations in new genes and in cases outside of current germline testing criteria.
At the ACMG annual conference in Phoenix last week, several labs and companies discussed their efforts in healthy genome sequencing.
This week's news includes Ambry Genetics, DNAstack, Protea Biosciences Group, Exosome Diagnostics, BGI Europe, and Castle Biosciences.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.